Aktienanalyse zu PTC Therapeutics Inc (PTCT)PTCTPTC Therapeutics Inc

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

PTC Therapeutics Inc is a good buy right now due to its recent strong earnings report, which showed a Q2 GAAP EPS of $0.92, exceeding expectations by $0.71, and a revenue of $360.5 million, marking a 101.5% year-over-year increase. Additionally, the stock has a forward P/E of 39.68, indicating growth potential, while analysts have set price targets significantly above the current price of $70.09, with the highest target at $109. The main risk is the current RSI of 37.045, suggesting that the stock is oversold, but this can also present a buying opportunity.

8 analysts cover PTCT: 2 rate it Buy, 5 Hold and 1 Sell. The average price target is 78.18.